Marasini Nirmal, Fu Changkui, Fletcher Nicholas L, Subasic Christopher, Er Gerald, Mardon Karine, Thurecht Kristofer J, Whittaker Andrew K, Kaminskas Lisa M
School of Biomedical Sciences, The University of Queensland, St Lucia 4072, Queensland, Australia.
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia 4072, Queensland, Australia.
Nanomaterials (Basel). 2020 Dec 8;10(12):2452. doi: 10.3390/nano10122452.
A better understanding of the impact of molecular size and linkers is important for PEG-based hyperbranched polymers (HBPs) intended as tailored drug delivery vehicles. This study aimed to evaluate the effects of crosslinker chemistry (cleavable disulphide versus non-cleavable ethylene glycol methacrylate (EGDMA) linkers) and molecular weight within the expected size range for efficient renal elimination (22 vs. 48 kDa) on the intravenous pharmacokinetic and biodistribution properties of Zr-labelled HBPs in rats. All HBPs showed similar plasma pharmacokinetics over 72 h, despite differences in linker chemistry and size. A larger proportion of HBP with the cleavable linker was eliminated via the urine and faeces compared to a similar-sized HBP with the non-cleavable linker, while size had no impact on the proportion of the dose excreted. The higher molecular weight HBPs accumulated in organs of the mononuclear phagocyte system (liver and spleen) more avidly than the smaller HBP. These results suggest that HBPs within the 22 to 48 kDa size range show no differences in plasma pharmacokinetics, but distinct patterns of organ biodistribution and elimination are evident.
对于旨在作为定制药物递送载体的聚乙二醇基超支化聚合物(HBP)而言,更好地理解分子大小和连接体的影响非常重要。本研究旨在评估交联剂化学性质(可裂解二硫键与不可裂解的甲基丙烯酸乙二醇酯(EGDMA)连接体)以及在有效肾清除预期大小范围内的分子量(22 kDa与48 kDa)对大鼠体内锆标记的HBP静脉药代动力学和生物分布特性的影响。尽管连接体化学性质和大小存在差异,但所有HBP在72小时内均表现出相似的血浆药代动力学。与具有不可裂解连接体的类似大小的HBP相比,具有可裂解连接体的HBP通过尿液和粪便排出的比例更高,而大小对排出剂量的比例没有影响。较高分子量的HBP比小分子HBP更易在单核吞噬细胞系统的器官(肝脏和脾脏)中蓄积。这些结果表明,22至48 kDa大小范围内的HBP在血浆药代动力学上没有差异,但器官生物分布和清除的明显模式是显而易见的。